Accordingly, the concomitant inhibition of VEGF and MET signaling has been determined as a key point for overcoming the resistance to a prior antiangiogenic treatment, such as sunitinib (SUN), the only multi-targeted tyrosine kinase inhibitor (TKI) approved for pancreatic NETs (Raymond et al. 2011, Yao et al. 2011). Here, MET is linked to pancreatic neuroendocrine tumor.